EUVIMEDEUVIMED entdecken
Crossref

Glucagon-like peptide-1 receptor agonists (GLP-1RA) in dermatology: Mechanistic insights, therapeutic potential and adverse effects

Vishal Gaurav, Archana Singal

Indian Journal of Dermatology, Venereology and Leprology · 19.11.2026 · 1-14

DOI: 10.25259/ijdvl_127_2026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, online erschienen am 19.11.2026. Verfasst von Vishal Gaurav und 1 weiteren Autor:innen. Die Arbeit nennt 100 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as important metabolic therapies with expanding relevance in dermatology due to their pleiotropic immunomodulatory, anti-inflammatory and regenerative effects. This narrative review synthesises evidence from preclinical studies, clinical trials, observational cohorts and case reports (2005-2025) to evaluate their dermatologic applications and safety profile. GLP-1 receptors are expressed in keratinocytes, immune cells and dermal fibroblasts, enabling both indirect metabolic and direct cutaneous effects. Systemic benefits include weight loss, improved insulin sensitivity and reduction of chronic low-grade inflammation, while direct actions involve inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signalling, down regulation of Th1/Th17 cytokines, modulation of immune cell trafficking and activation of phosphatidylinositol-3-kinase (PI3K)/Akt pathways that promote keratinocyte migration and wound repair. Clinically, the most consistent benefits are observed in psoriasis and hidradenitis suppurativa, particularly in patients with obesity, insulin resistance or type 2 diabetes, where both weight-dependent and independent mechanisms contribute. Evidence for wound healing is promising but largely preclinical or observational, whereas data in atopic dermatitis remain limited and suggest possible drug-induced eczematous reactions rather than therapeutic benefit. GLP-1RAs also influence aesthetic outcomes through fat redistribution and skin changes. Cutaneous adverse effects are generally mild, with injection-site reactions being most common; however, hypersensitivity reactions and rare immune-mediated conditions such as bullous pemphigoid have been reported. Systemic adverse effects and recent regulatory concerns regarding misuse further underscore the need for careful patient selection and monitoring. Overall, GLP-1RAs represent adjunctive metabolically targeted therapies in dermatology with future randomised trials required to define their precise therapeutic role.

Zitieren

APA

Gaurav, V., & Singal, A. (2026). Glucagon-like peptide-1 receptor agonists (GLP-1RA) in dermatology: Mechanistic insights, therapeutic potential and adverse effects. Indian Journal of Dermatology, Venereology and Leprology, 0, 1-14. https://doi.org/10.25259/ijdvl_127_2026

Vancouver

Gaurav V, Singal A. Glucagon-like peptide-1 receptor agonists (GLP-1RA) in dermatology: Mechanistic insights, therapeutic potential and adverse effects. Indian Journal of Dermatology, Venereology and Leprology. 2026;0:1-14. doi:10.25259/ijdvl_127_2026

BibTeX
@article{Gaurav2026,
  author = {Gaurav, Vishal and Singal, Archana},
  title = {Glucagon-like peptide-1 receptor agonists (GLP-1RA) in dermatology: Mechanistic insights, therapeutic potential and adverse effects},
  journal = {Indian Journal of Dermatology, Venereology and Leprology},
  year = {2026},
  volume = {0},
  pages = {1--14},
  doi = {10.25259/ijdvl_127_2026}
}
Kostenlos starten →